RAMM Pharma Corp. (CSE:RAMM)
Canada
· Delayed Price · Currency is CAD 0.0200
0.00 (0.00%)
Feb 4, 2025, 12:00 PM EDT
RAMM Pharma Income Statement
Financials in millions CAD. Fiscal year is November - October.
Millions CAD. Fiscal year is Nov - Oct.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jan '25 Jan 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | Oct '20 Oct 31, 2020 | 2018 - 2019 |
| Revenue | 4.4 | 4.34 | 5.07 | 3.9 | 4.12 | 5.44 | Upgrade
|
| Revenue Growth (YoY) | -6.32% | -14.28% | 29.97% | -5.31% | -24.40% | -2.96% | Upgrade
|
| Cost of Revenue | 2.65 | 2.57 | 4.64 | 3.41 | 4.15 | 4.17 | Upgrade
|
| Gross Profit | 1.75 | 1.78 | 0.42 | 0.48 | -0.04 | 1.27 | Upgrade
|
| Selling, General & Admin | 8.14 | 8.42 | 7.36 | 8.42 | 6.6 | 8.85 | Upgrade
|
| Other Operating Expenses | 0.12 | 0.12 | 0.15 | - | - | - | Upgrade
|
| Operating Expenses | 10.43 | 10.72 | 7.51 | 8.42 | 6.6 | 8.85 | Upgrade
|
| Operating Income | -8.68 | -8.94 | -7.09 | -7.94 | -6.64 | -7.58 | Upgrade
|
| Interest Expense | -0.04 | -0.04 | -0.05 | -0.01 | -0.01 | -0.06 | Upgrade
|
| Interest & Investment Income | 0 | 0.03 | 0.2 | 0.16 | 0.37 | 0.33 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | -0.71 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.11 | -0 | -0.04 | 0.08 | -0.3 | -0.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.11 | 0.02 | 0.35 | 0.17 | 0.03 | - | Upgrade
|
| EBT Excluding Unusual Items | -8.51 | -8.93 | -6.64 | -7.54 | -7.26 | -7.43 | Upgrade
|
| Impairment of Goodwill | - | - | - | -12.93 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -0.23 | 0.27 | - | Upgrade
|
| Asset Writedown | -6.8 | -7.56 | -1.07 | -0.25 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.11 | - | Upgrade
|
| Pretax Income | -15.31 | -16.49 | -7.71 | -20.95 | -7.1 | -7.43 | Upgrade
|
| Income Tax Expense | -0.08 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | Upgrade
|
| Net Income | -15.23 | -16.5 | -7.72 | -20.96 | -7.11 | -7.43 | Upgrade
|
| Net Income to Common | -15.23 | -16.5 | -7.72 | -20.96 | -7.11 | -7.43 | Upgrade
|
| Shares Outstanding (Basic) | 119 | 119 | 121 | 123 | 108 | 101 | Upgrade
|
| Shares Outstanding (Diluted) | 119 | 119 | 121 | 123 | 108 | 101 | Upgrade
|
| Shares Change (YoY) | -0.76% | -1.36% | -1.42% | 13.20% | 7.85% | 99.46% | Upgrade
|
| EPS (Basic) | -0.13 | -0.14 | -0.06 | -0.17 | -0.07 | -0.07 | Upgrade
|
| EPS (Diluted) | -0.13 | -0.14 | -0.06 | -0.17 | -0.07 | -0.07 | Upgrade
|
| Free Cash Flow | -3.12 | -4.05 | -4.4 | -6.08 | -4.26 | -3.19 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.03 | -0.04 | -0.05 | -0.04 | -0.03 | Upgrade
|
| Gross Margin | 39.79% | 40.92% | 8.34% | 12.43% | -0.91% | 23.40% | Upgrade
|
| Operating Margin | -197.50% | -205.86% | -139.90% | -203.64% | -161.37% | -139.14% | Upgrade
|
| Profit Margin | -346.45% | -380.06% | -152.43% | -537.79% | -172.66% | -136.47% | Upgrade
|
| Free Cash Flow Margin | -70.98% | -93.17% | -86.87% | -156.02% | -103.52% | -58.61% | Upgrade
|
| EBITDA | -7.84 | -7.97 | -6.03 | -7 | -6.01 | -7.24 | Upgrade
|
| EBITDA Margin | -178.23% | -183.47% | -119.00% | -179.69% | -145.94% | -132.89% | Upgrade
|
| D&A For EBITDA | 0.85 | 0.97 | 1.06 | 0.93 | 0.63 | 0.34 | Upgrade
|
| EBIT | -8.68 | -8.94 | -7.09 | -7.94 | -6.64 | -7.58 | Upgrade
|
| EBIT Margin | -197.50% | -205.86% | -139.90% | -203.64% | -161.37% | -139.14% | Upgrade
|
| Advertising Expenses | - | 0.06 | 0.2 | 0.42 | 0.09 | 0.08 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.